Vancomycin Tolerance
Download this product sheet. |
Reports of clinical failures from increasing vancomycin MICs in S. aureus are growing in frequency. 1,2 S. aureus isolates with vancomycin MICs greater than or equal to 1.5 µg/mL have shown to lead to more than double the likelihood of clinical failure over the more normally observed population of less than or equal to 1 µg/mL – resulting in failures as high as 36-percent.2 MicroPhage proposes to introduce the first product designed to rapidly assess patients for reduced vancomycin susceptibilities or "vancomycin MIC creep." Using our bacteriophage amplification platform, the MicroPhage Vancomycin Tolerance Test will work in parallel with the MicroPhage MRSA/MSSA Blood Culture Test to determine if a known S. aureus has an elevated vancomycin MIC of 1.5 µg/mL or greater. By monitoring for these strains, clinicians can appropriately dose vancomycin or consider appropriate alternatives – days before traditional ID/AST results are available. This critical antibiotic information will ultimately help clinicians reduce suboptimal antibiotic treatments, complications, and costs, and thereby improve patient outcomes. |
- Monitor for increasing tolerance – Use with the MicroPhage MRSA/MSSA Blood Culture Test to quickly determine tolerance in BSI patients with prolonged exposure to vancomycin.
- Enable more effective treatments – Get critical antibiotic information to enable the most-appropriate treatment.
- Get definitive results faster than standard diagnostic methods – Receive culture quality results in hours, not days.
- Improve outcomes – Reduce suboptimal antibiotic treatments, complications, and costs.
- Simplify testing with a phenotypic test – Rely on viable bacteria for results that are directly related to the sample – no primers or molecular markers.
This test is not cleared by the U.S. FDA nor CE Marked and not yet available for sale.
- Gould. Int’l Jof Antimicrobial Agents, V.31, Page 1, 2009.
- Martin et al. Clin Biochem Rev. 2010 February; 31(1): 21–24.